Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3b safety study of intravitreal pegaptanib in diabetic macular edema
NL-OMON36645Phase 3Withdrawn
- Sponsor
- Pfizer
- Start
- Jan 2011
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pegaptanib sodium in diabetic macular edema (DME), sponsored by Pfizer. Planned start Jan 2011; status: withdrawn.
02
Drugs
pegaptanib sodium
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NL-OMON36645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36645.